News Category
PolyPeptide shareholders approved a full board reshuffle and removal of transfer restrictions, clearing the path for Samsung Biologics' tender offer a...
The UK's MHRA has mandated new antidepressant safety measures, including expanded suicide-risk warnings for all ages and recognition of persistent sex...
Cotecna's acquisition of Energon Labs strengthens its global life sciences platform and expands its pharmaceutical testing capabilities in India, a ke...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced that its subsidiary MindWave Innovations Inc. USA will list the NILA token on the Pio...
Nutriband's $1.75 million warrant exercise provides crucial funding for the clinical development and FDA submission of its abuse-deterrent fentanyl pa...
DuLac Farmaceutici is advancing its U.S. retail strategy by following up with prospective partners after the 2026 ECRM Vitamin, Weight Management & Sp...
Nutriband's patent application for improved aversive formulations and coating methods could extend protection for its AVERSA abuse-deterrent transderm...
VERAXA Biotech's FDA-aligned New Approach Methodologies could slash animal use by over 90% while accelerating preclinical development of its antibody-...
Nutriband Inc. celebrates its fifth anniversary on the Nasdaq Capital Market with a shareholder letter outlining milestones and future plans for its a...
Helus Pharma's legal name change from Cybin Inc. reflects its transition from a clinical-stage developer to a commercial-ready pharmaceutical company,...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate beyond discovery, planning final candidate engineering and preclinical studies...
Apimeds Pharmaceuticals' subsidiary MindWave Innovations will develop and operate FlashChain, a blockchain for tracking digital broadcasting rights, v...
Creative Biolabs is connecting glycoprotein development with glycan characterization to help researchers understand how production-related variations ...
Helus Pharma's shareholders approved a legal name change from Cybin Inc. and elected eight directors, marking the company's transition from a clinical...
Nutriband Inc. (NASDAQ: NTRB) will let its outstanding warrants expire on Sept. 30, 2026, with no extension or repricing, potentially raising $5.86 mi...
Peptide Wholesale Supply has expanded its HPLC verification protocols to bulk orders of BPC-157, Semaglutide, and Tirzepatide, providing researchers w...
Telomir Pharmaceuticals' Telomir-Zn inhibits growth in human and canine osteosarcoma cell lines at low concentrations, supporting further studies that...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing therapies to overcome cancer drug...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a novel myelin repair candidate, marks a pivotal step in potentially changing the M...
Nutriband received a USPTO Notice of Publication for trademarks related to its abuse-deterrent fentanyl patch, moving closer to commercialization and ...
Quantum BioPharma's lead drug candidate Lucid-MS for progressive multiple sclerosis has drawn a 'Buy' rating from Rodman & Renshaw, signaling confiden...
Earth Science Tech's acquisition of Zoolzy LLC enhances its compounding pharmacy operations by providing access to APIs at competitive prices, boostin...
DuLac Farmaceutici accelerates its U.S. expansion by launching on OneLavi and preparing for ECRM meetings, leveraging Amazon success to target major r...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate into preclinical development, signaling progress in its oncology pipeline and ...
Onco-Innovations' LOI to acquire exclusive rights to Ifowonco's oral small-molecule LAG-3 inhibitor program could position the company at the forefron...
Earth Science Tech's acquisition of Zoolzy is strategically important as it enhances its compounding pharmacies' access to APIs at competitive prices ...
SCHOTT Pharma's parent group's updated climate targets, validated by SBTi, now include absolute Scope 3 reductions, shifting focus from supplier commi...
Helus Pharma reported progress in its Phase 3 program for HLP003 in major depressive disorder, with enrollment completed and topline data expected in ...
VERAXA Biotech has advanced its VXA-222 bispecific antibody-drug conjugate into the next development stage and expanded its patent portfolio, strength...
Tonix Pharmaceuticals has received FDA feedback supporting a Phase 2 field study for its Lyme disease prevention candidate, TNX-4800, marking a signif...
VERAXA Biotech’s bispecific ADC program VXA-222 reaches a key milestone, moving to the next phase of development under its OmniAb collaboration, poten...
VERAXA Biotech announced the appointment of Dr. Christoph Erkel as Chief Scientific Officer, bringing extensive experience in antibody therapeutics to...
NanoViricides secured $3.8 million through a registered direct offering with a single institutional investor, providing capital to advance its lead an...
VERAXA Biotech AG appointed Christoph Erkel as Chief Scientific Officer to lead the development of its BiTAC platform for solid tumor cancer therapies...
VERAXA Biotech received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE program, reducing development uncertainty bef...
VERAXA Biotech AG received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity for non-clinical deve...
Siegfried has appointed Eduardo Montanha as COO, effective September 1, 2026, to lead the newly combined Drug Substances and Drug Products operations,...
NextPlat Corp announced an agreement to acquire an independent pharmacy in rural Florida, expanding its PharmcoRx network and targeting underserved ma...
Onco-Innovations Limited announced the completion of its analytical reference standard preparation program for ONC010, a key step in strengthening its...
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program in partnership with ATUM, marking a critical step toward ...
The global sustained release polymers market is projected to grow at a CAGR of 7.4% from 2026 to 2036, driven by increasing chronic disease prevalence...
VERAXA Biotech provided a corporate update highlighting progress in its BiTAC platform and increasing pharmaceutical interest, aiming to advance lead ...
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM, following encouraging prec...
The article highlights the importance of early-stage partnerships and licensing deals in antibody therapeutics, particularly ADCs and T-cell engagers,...
Ace Therapeutics announces end-to-end preclinical services for analgesic drug development, featuring diverse in vivo pain models and a complete suite ...
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve profitability, affecting 32 employees, as ...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for major depressive disorder, with topline data expected in Q4...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
